CEO Andy McNeill and client, Christine Damico of Johnson & Johnson, talk about the changing face of pharmaceutical meetings. With many off-patent drugs coming up, cut-backs are discussed such as the size, length and frequency of face-to-face meetings. This article offers insight from the perspective of both the pharmaceutical company and meeting planners alike. Despite the recession, it is agreed that corporate meetings are a very effective way to gather information, train staff, and get doctors comfortable with new and potential drugs.
Strategic Meetings Management
Expert Strategies and ProcessesThat Save You MoneyOur strategy focuses on methods, budgeting processes, bidding and...